cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established Novo's CagriSema loses phase 3

BPC-157 is available in both injectable and oral forms, which makes it versatile for different goals

It has also been shown to upregulate the expression of the early growth response gene-1 (Egr-1), a transcription factor that orchestrates the expression of multiple growth factors involved in wo Research Evidence Promotes VEGFR2-mediated angiogenesis in preclinical wound models (McGuire et al., 2025)Stimulates fibroblast migration and tendon outgrowth in ex vivo explant studies (Sikiric et al., 2021)Upregulates Egr-1 transcription factor, driving growth factor expression cascadeDemonstrates stability under physiological conditions due to high proline contentModulates nitric oxide signaling pathways in gastrointestinal and vascular tissue models Bottom line: BPC-157 is one of the most extensively studied synthetic peptides in preclinical regenerative research

Intramuscular Injection Used in a smaller subset of rodent studies

Worried about these feelings after starting B12 shots

The chart below provides guidance for specific situations

We will evaluate your health history, current condition, and weight loss goals to determine if AOD-9604 is right for you